Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Glofitamab, Poseltinib and Lenalidomide in patients with relapsed/refractory diffuse large B cell lymphoma
KCT0007113Phase 2Recruiting
- Sponsor
- Roche
- Start
- May 2022
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab, poseltinib, lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Started May 2022; status: recruiting.
02
Drugs
glofitamabposeltiniblenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0007113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007113.